Seqens (www.pcisynthesis.com), a Boston-based Contract Manufacturing Organization (CMO) that manufacturers new chemical entities (NCEs), generic active pharmaceutical ingredients (APIs), and complex specialty chemicals, today announced the general availability of phosphonic acids, widely used by researchers and developers of nano-particle technology applications around the world, and the launch of its new web page phosphonicacid.com.
Ed Price, president of Seqens, said, “More than 200 of our worldwide customers and academic partners use Seqens’s phosphonic acids today. Innovation and quality have long been hallmarks of Seqens, and our phosphonic product line is the latest example.”
Seqens’s growing industry reputation is reflected in its latest industry accolades: Seqens just won four categories of the 2013 Life Science Leader CMO Leadership Awards for quality, innovation, productivity and reliability.
Phosphonic acids have wide commercial use as surfactants for the manufacture of a host of different nano-particle technologies, used in the electronics and alternative energy industries. Phosphonic acids also have unique properties as chelating agents that can be utilized in certain specific microelectronic applications as well. For more than 10 years Seqens’s phosphonic acids have been used widely by nanotechnology manufacturers, governments and research institutions around the world.
“We manufacture eight phosphonic acids today, available in small quantities such as 10g all the way up to several metric tons,” concluded Price, “We have developed processes that produce these materials in very high purity and low metals content. We have also developed sophisticated analytical tools that allow us to analyze these materials.”
For more information about Seqens’s phosphonic acids product line, please visit: phosphonicacid.com.
Seqens is a 13-year-old custom chemical manufacturer of new chemical entities (NCEs), generic active pharmaceutical ingredients (APIs), and other specialty chemical products. A contract manufacturing organization (CMO), Seqens provides emerging and mid-sized pharmaceutical companies access to the expertise needed to develop and manufacture complex small molecules and APIs used in generic pharmaceuticals. To learn more about Seqens, its proprietary NCE development activities and process R&D capabilities please visit www.pcisynthesis.com.